Glenmark Pharma gets final USFDA nod for generic version of Abiraterone Acetate tabs
PTI, May 20, 2022, 10:19 AM IST
New Delhi: Glenmark Pharmaceuticals Ltd on Friday said its US arm has received final approval from the US health regulator for its generic version of Abiraterone Acetate tablets used for the treatment of prostate cancer.
The approval granted by the US Food and Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for Abiraterone Acetate tablets of strength of 500 mg, the company said in a statement.
It is the generic version of Zytiga tablets, 500 mg, of Janssen Biotech Inc, it added.
Citing IQVIA sales data for the 12-month period ended March 2022, the company said Zytiga tablets 500 mg achieved annual sales of approximately USD 260.2 million.
Glenmark said its current portfolio consists of 173 products authorized for distribution in the US marketplace and 49 abbreviated new drug applications pending approval with the USFDA.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
Father’s diet can affect anxiety in sons, metabolism in daughters: Study in mice finds
Low back pain, depression, headaches main causes of poor health: Study
Surgical options for Parkinson’s disease
MUST WATCH
Latest Additions
NIA arrests key accused in 2023 attack on Indian High Commission in London
Three persons run over by train in Bengaluru
Indian nationals aboard ‘MSC Aries’ in good health, return delayed due to technicalities: MEA
Husband has no control over wife’s ‘stridhan’: SC
IT sleuths threatening raided leaders to claim money belongs to me, Cong: DK Shivakumar